Unlock New Insights with Selective Measurement of BD-Tau

Flyer

 

Brain-derived tau (BD-Tau) is enhancing our understanding of neurodegenerative diseases. As an emerging bloodbased biomarker, BD-Tau is demonstrating potential in distinguishing Alzheimer’s disease (AD) from other neurodegenerative conditions, predicting cognitive decline in AD subgroups, and assessing severe traumatic brain injury (sTBI). The Simoa® BD-Tau Advantage PLUS assay (104797) provides ultra-sensitive and selective measurement of BD-Tau proteins in biological samples. This assay offers new insights to advance research into AD and other neurological conditions. Download our flyer to learn more.

By submitting the form you agree to Quanterix’s Terms and Conditions. If you have subscribed to our email marketing you can unsubscribe at any time, and you can learn more about how we manage your personal details in our Privacy Policy.